Your browser doesn't support javascript.
loading
Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression.
Conde, João; Pumroy, Ruth A; Baker, Charlotte; Rodrigues, Tiago; Guerreiro, Ana; Sousa, Bárbara B; Marques, Marta C; de Almeida, Bernardo P; Lee, Sohyon; Leites, Elvira P; Picard, Daniel; Samanta, Amrita; Vaz, Sandra H; Sieglitz, Florian; Langini, Maike; Remke, Marc; Roque, Rafael; Weiss, Tobias; Weller, Michael; Liu, Yuhang; Han, Seungil; Corzana, Francisco; Morais, Vanessa A; Faria, Cláudia C; Carvalho, Tânia; Filippakopoulos, Panagis; Snijder, Berend; Barbosa-Morais, Nuno L; Moiseenkova-Bell, Vera Y; Bernardes, Gonçalo J L.
Afiliação
  • Conde J; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Pumroy RA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Baker C; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Rodrigues T; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Guerreiro A; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Sousa BB; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Marques MC; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • de Almeida BP; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Lee S; Institute of Molecular Systems Biology, ETH Zürich, Otto-Stern-Weg 3, 8093 Zürich, Switzerland.
  • Leites EP; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Picard D; Department of Pediatric Neuro-Oncogenomics, DKFZ, Heidelberg 69120, Germany.
  • Samanta A; Department of Pediatric Neuro-Oncogenomics, DKTK, Essen D-45147, Germany.
  • Vaz SH; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf 40225, Germany.
  • Sieglitz F; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Langini M; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Remke M; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Roque R; Department of Pediatric Neuro-Oncogenomics, DKFZ, Heidelberg 69120, Germany.
  • Weiss T; Department of Pediatric Neuro-Oncogenomics, DKTK, Essen D-45147, Germany.
  • Weller M; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf 40225, Germany.
  • Liu Y; Department of Pediatric Neuro-Oncogenomics, DKFZ, Heidelberg 69120, Germany.
  • Han S; Department of Pediatric Neuro-Oncogenomics, DKTK, Essen D-45147, Germany.
  • Corzana F; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf 40225, Germany.
  • Morais VA; Laboratório de Neuropatologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) EPE, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Faria CC; Department of Neurology and Brain Tumour Center, University Hospital Zürich and University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.
  • Carvalho T; Department of Neurology and Brain Tumour Center, University Hospital Zürich and University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.
  • Filippakopoulos P; Discovery Sciences, Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States.
  • Snijder B; Discovery Sciences, Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States.
  • Barbosa-Morais NL; Departamento de Química, Universidad de La Rioja, 26006 Logroño, Spain.
  • Moiseenkova-Bell VY; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
  • Bernardes GJL; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
ACS Cent Sci ; 7(5): 868-881, 2021 May 26.
Article em En | MEDLINE | ID: mdl-34079902
ABSTRACT
The use of computational tools to identify biological targets of natural products with anticancer properties and unknown modes of action is gaining momentum. We employed self-organizing maps to deconvolute the phenotypic effects of piperlongumine (PL) and establish a link to modulation of the human transient receptor potential vanilloid 2 (hTRPV2) channel. The structure of the PL-bound full-length rat TRPV2 channel was determined by cryo-EM. PL binds to a transient allosteric pocket responsible for a new mode of anticancer activity against glioblastoma (GBM) in which hTRPV2 is overexpressed. Calcium imaging experiments revealed the importance of Arg539 and Thr522 residues on the antagonistic effect of PL and calcium influx modulation of the TRPV2 channel. Downregulation of hTRPV2 reduces sensitivity to PL and decreases ROS production. Analysis of GBM patient samples associates hTRPV2 overexpression with tumor grade, disease progression, and poor prognosis. Extensive tumor abrogation and long term survival was achieved in two murine models of orthotopic GBM by formulating PL in an implantable scaffold/hydrogel for sustained local therapy. Furthermore, in primary tumor samples derived from GBM patients, we observed a selective reduction of malignant cells in response to PL ex vivo. Our results establish a broadly applicable strategy, leveraging data-motivated research hypotheses for the discovery of novel means tackling cancer.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Cent Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Cent Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA